智通财经网·2025-12-09 12:12Group 1 - The core point of the news is that Fosun Pharma has signed a licensing agreement with Pfizer for the development and commercialization of the oral small molecule GLP-1 receptor agonist YP05002, granting Pfizer exclusive rights globally across various therapeutic areas [1][2] - Under the agreement, Fosun Pharma's subsidiary, YaoYao Pharmaceutical, will receive an upfront payment of $150 million and up to $350 million in milestone payments based on clinical and commercialization progress [1] - Additionally, Fosun Pharma could earn up to $1.585 billion in sales milestone payments based on the annual net sales performance of the licensed product [1] Group 2 - YP05002 is an oral small molecule GLP-1 receptor agonist developed by the company, aimed at treating type 2 diabetes, obesity, and related diseases by promoting insulin secretion and reducing glucagon secretion [2] - The potential indications for YP05002 include long-term weight management, type 2 diabetes, and metabolic dysfunction-related fatty liver disease (non-alcoholic steatohepatitis) [2]